A Study To Estimate the Anti-Tumor Activity And Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

Type of Cancer
Skin and Soft Tissue

Sponsor
Gerogetown

Protocol Number
CA209-763

To Learn More Call
(201)-510-0950